{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T08:01:02Z","timestamp":1793952062299,"version":"4.8.0"},"reference-count":90,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2020,8,25]],"date-time":"2020-08-25T00:00:00Z","timestamp":1598313600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,10]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose of review<\/jats:title>\n                    <jats:p>Discoveries of myositis-specific antibodies, transcriptomic signatures, and clinicoseropathological correlation support classification of idiopathic inflammatory myopathies (IIM) into four major subgroups: dermatomyositis, immune-mediated necrotizing myopathy (IMNM), antisynthetase syndrome (ASS), and inclusion body myositis (IBM) whereas leaving polymyositis as a historical nonspecific diagnosis of exclusion. This review summarizes and comments on recent knowledge regarding the major subgroup of IIM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent findings<\/jats:title>\n                    <jats:p>Type 1 interferon (IFN1) pathway activation is the most prominent in dermatomyositis whereas type 2 interferon (IFN2) pathway activation is high in IBM and ASS; neither pathway is distinct in IMNM. Myxovirus-resistant protein A, IFN1 surrogate marker, is now one of definite dermatomyositis muscle biopsy criteria in the new 2018 European Neuromuscular Centre classification of dermatomyositis; the classification emphasizes on different categorization with and without dermatomyositis-specific antibody result. Novel HLA loci associated with anti-TIF1-\u03b3, anti-Mi-2, and anti-Jo-1 antibodies in Caucasian population are identified. Associations of chaperon-assisted selective autophagy (CASA) and complement-mediated autoimmunity in IMNM as well as highly differentiated T cells in IBM are discovered.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Current IIM classification requires integrated clinicoseropathological approaches. Additional information, such as transcriptomics, HLA haplotyping, and potential biomarkers help tailoring categorization that may have future diagnostic and therapeutic implications.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/wco.0000000000000855","type":"journal-article","created":{"date-parts":[[2020,8,26]],"date-time":"2020-08-26T22:01:10Z","timestamp":1598479270000},"page":"590-603","source":"Crossref","is-referenced-by-count":115,"title":["Where are we moving in the classification of idiopathic inflammatory myopathies?"],"prefix":"10.1097","volume":"33","author":[{"given":"Jantima","family":"Tanboon","sequence":"first","affiliation":[{"name":"Department of Neuromuscular Research, National Institute of Neuroscience, National Center of Neurology and Psychiatry (NCNP), Tokyo, Japan"},{"name":"Department of Genome Medicine Development, Medical Genome Center (MGC), National Center of Neurology and Psychiatry (NCNP), Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akinori","family":"Uruha","sequence":"additional","affiliation":[{"name":"Department of Neuropathology, Charit\u00e9 - Universit\u00e4tsmedizin, Berlin, Corporate Member of Freie Universit\u00e4t Berlin, Humboldt-Universit\u00e4t zu Berlin, and Berlin Institute of Health (BIH), Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Werner","family":"Stenzel","sequence":"additional","affiliation":[{"name":"Department of Neuropathology, Charit\u00e9 - Universit\u00e4tsmedizin, Berlin, Corporate Member of Freie Universit\u00e4t Berlin, Humboldt-Universit\u00e4t zu Berlin, and Berlin Institute of Health (BIH), Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichizo","family":"Nishino","sequence":"additional","affiliation":[{"name":"Department of Neuromuscular Research, National Institute of Neuroscience, National Center of Neurology and Psychiatry (NCNP), Tokyo, Japan"},{"name":"Department of Genome Medicine Development, Medical Genome Center (MGC), National Center of Neurology and Psychiatry (NCNP), Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,8,25]]},"reference":[{"key":"R1-20230925","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1056\/NEJM197502132920706","article-title":"Polymyositis and dermatomyositis (first of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N Engl J Med"},{"key":"R2-20230925","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJM197502202920807","article-title":"Polymyositis and dermatomyositis (second of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N Engl J Med"},{"key":"R3-20230925","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1056\/NEJM199111213252107","article-title":"Polymyositis, dermatomyositis and inclusion-body myositis","volume":"325","author":"Dalakas","year":"1991","journal-title":"N Engl J Med"},{"key":"R4-20230925","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1002\/ana.410380504","article-title":"Inclusion body myositis and myopathies","volume":"38","author":"Griggs","year":"1995","journal-title":"Ann Neurol"},{"key":"R5-20230925","first-page":"668","article-title":"Classification criteria for polymyositis and dermatomyositis","volume":"22","author":"Tanimoto","year":"1995","journal-title":"J Rheumatol"},{"key":"R6-20230925","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1097\/00002281-199711000-00008","article-title":"Classification criteria for the idiopathic inflammatory myopathies","volume":"9","author":"Targoff","year":"1997","journal-title":"Curr Opin Rheumatol"},{"key":"R7-20230925","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(03)14368-1","article-title":"Polymyositis and dermatomyositis","volume":"362","author":"Dalakas","year":"2003","journal-title":"Lancet"},{"key":"R8-20230925","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.nmd.2004.02.006","article-title":"119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10\u201312 October 2003, Naarden, The Netherlands","volume":"14","author":"Hoogendijk","year":"2004","journal-title":"Neuromuscul Disord"},{"key":"R9-20230925","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1212\/WNL.0000000000000642","article-title":"Evaluation and construction of diagnostic criteria for inclusion body myositis","volume":"83","author":"Lloyd","year":"2014","journal-title":"Neurology"},{"key":"R10-20230925","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.nmd.2013.08.007","article-title":"188th ENMC International Workshop: Inclusion Body Myositis, 2\u20134 December 2011, Naarden, The Netherlands","volume":"23","author":"Rose","year":"2013","journal-title":"Neuromuscul Disord"},{"key":"R11-20230925","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1136\/annrheumdis-2017-211468","article-title":"2017 European League Against Rheumatism\/American College of Rheumatology Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies and Their Major Subgroups","volume":"76","author":"Lundberg","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"R12-20230925","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1136\/annrheumdis-2017-211468","article-title":"2017 European League Against Rheumatism\/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups","volume":"76","author":"Lundberg","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"R13-20230925","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1097\/BOR.0b013e32834bab42","article-title":"Acquired immune and inflammatory myopathies: pathologic classification","volume":"23","author":"Pestronk","year":"2011","journal-title":"Curr Opin Rheumatol"},{"key":"R14-20230925","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1097\/00005792-199111000-00002","article-title":"A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups","volume":"70","author":"Love","year":"1991","journal-title":"Medicine (Baltimore)"},{"key":"R15-20230925","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/01.md.0000173991.74008.b0","article-title":"Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100 French Canadian patients","volume":"84","author":"Troyanov","year":"2005","journal-title":"Medicine (Baltimore)"},{"key":"R16-20230925","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1001\/jamaneurol.2018.2598","article-title":"Development of a new classification system for idiopathic inflammatory myopathies based on clinical manifestations and myositis-specific autoantibodies","volume":"75","author":"Mariampillai","year":"2018","journal-title":"JAMA Neurol"},{"key":"R17-20230925","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.nmd.2017.09.016","article-title":"224th ENMC International Workshop: clinico-sero-pathological classification of immune-mediated necrotizing myopathies Zandvoort, The Netherlands, 14\u201316 October 2016","volume":"28","author":"Allenbach","year":"2018","journal-title":"Neuromuscul Disord"},{"key":"R18-20230925","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.nmd.2019.10.005","article-title":"239th ENMC International Workshop: classification of dermatomyositis, Amsterdam, the Netherlands, 14\u201316 December 2018","volume":"30","author":"Mammen","year":"2020","journal-title":"Neuromuscul Disord"},{"key":"R19-20230925","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1097\/WCO.0000000000000376","article-title":"Advances in serological diagnostics of inflammatory myopathies","volume":"29","author":"Benveniste","year":"2016","journal-title":"Curr Opin Neurol"},{"key":"R20-20230925","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/nrrheum.2018.56","article-title":"Autoantibodies in myositis","volume":"14","author":"McHugh","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"R21-20230925","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/ana.20464","article-title":"Interferon-alpha\/beta-mediated innate immune mechanisms in dermatomyositis","volume":"57","author":"Greenberg","year":"2005","journal-title":"Ann Neurol"},{"key":"R22-20230925","doi-asserted-by":"crossref","first-page":"e000811","DOI":"10.1136\/rmdopen-2018-000811","article-title":"Distinct interferon signatures stratify inflammatory and dysimmune myopathies","volume":"5","author":"Rigolet","year":"2019","journal-title":"RMD Open"},{"key":"R23-20230925","doi-asserted-by":"crossref","first-page":"e1193","DOI":"10.1212\/WNL.0000000000008128","article-title":"Identification of distinctive interferon gene signatures in different types of myositis","volume":"93","author":"Pinal-Fernandez","year":"2019","journal-title":"Neurology"},{"key":"R24-20230925","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1212\/01.wnl.0000277527.69388.fe","article-title":"Correlation of muscle biopsy, clinical course, and outcome in PM and sporadic IBM","volume":"70","author":"Chahin","year":"2008","journal-title":"Neurology"},{"key":"R25-20230925","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1212\/WNL.61.3.288","article-title":"Unicorns, dragons, polymyositis, and other mythological beasts","volume":"61","author":"Amato","year":"2003","journal-title":"Neurology"},{"key":"R26-20230925","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.nmd.2014.12.001","article-title":"205th ENMC International Workshop: pathology diagnosis of idiopathic inflammatory myopathies part II 28\u201330 March 2014, Naarden, The Netherlands","volume":"25","author":"De Bleecker","year":"2015","journal-title":"Neuromuscul Disord"},{"key":"R27-20230925","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1093\/brain\/awy105","article-title":"JAK inhibitor improves type I interferon induced damage: proof of concept in dermatomyositis","volume":"141","author":"Ladislau","year":"2018","journal-title":"Brain"},{"key":"R28-20230925","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/ana.21805","article-title":"Interferon-stimulated gene 15 (ISG15) conjugates proteins in dermatomyositis muscle with perifascicular atrophy","volume":"67","author":"Salajegheh","year":"2010","journal-title":"Ann Neurol"},{"key":"R29-20230925","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1212\/WNL.0000000000003568","article-title":"Sarcoplasmic MxA expression: a valuable marker of dermatomyositis","volume":"88","author":"Uruha","year":"2017","journal-title":"Neurology"},{"key":"R30-20230925","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1186\/s13075-017-1383-0","article-title":"RIG-I expression in perifascicular myofibers is a reliable biomarker of dermatomyositis","volume":"19","author":"Su\u00e1rez-Calvet","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"R31-20230925","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/nan.12498","article-title":"Expression of myxovirus-resistance protein A: a possible marker of muscle disease activity and autoantibody specificities in juvenile dermatomyositis","volume":"45","author":"Soponkanaporn","year":"2019","journal-title":"Neuropathol Appl Neurobiol"},{"key":"R32-20230925","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/nan.12519","article-title":"Diagnostic potential of sarcoplasmic myxovirus resistance protein A expression in subsets of dermatomyositis","volume":"45","author":"Uruha","year":"2019","journal-title":"Neuropathol Appl Neurobiol"},{"key":"R33-20230925","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/nan.12551","article-title":"Absence of sarcoplasmic myxovirus resistance protein A (MxA) expression in antisynthetase syndrome in a cohort of 194 cases","volume":"45","author":"Inoue","year":"2019","journal-title":"Neuropathol Appl Neurobiol"},{"key":"R34-20230925","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1097\/WCO.0000000000000740","article-title":"Classification of idiopathic inflammatory myopathies: pathology perspectives","volume":"32","author":"Tanboon","year":"2019","journal-title":"Curr Opin Neurol"},{"key":"R35-20230925","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1002\/art.38093","article-title":"Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1\u03b3","volume":"65","author":"Fiorentino","year":"2013","journal-title":"Arthritis Rheum"},{"key":"R36-20230925","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1186\/s13075-017-1469-8","article-title":"Identification of multiple cancer-associated myositis-specific autoantibodies in idiopathic inflammatory myopathies: a large longitudinal cohort study","volume":"19","author":"Yang","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"R37-20230925","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jaut.2019.04.001","article-title":"Frequency, mutual exclusivity and clinical associations of myositis autoantibodies in a combined European cohort of idiopathic inflammatory myopathy patients","volume":"101","author":"Betteridge","year":"2019","journal-title":"J Autoimmun"},{"key":"R38-20230925","doi-asserted-by":"crossref","first-page":"e0154746","DOI":"10.1371\/journal.pone.0154746","article-title":"Oropharyngeal dysphagia in dermatomyositis: associations with clinical and laboratory features including autoantibodies","volume":"11","author":"Mugii","year":"2016","journal-title":"PLoS One"},{"key":"R39-20230925","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1212\/WNL.0000000000002863","article-title":"Anti-TIF1-\u03b3 antibody and cancer-associated myositis: A clinicohistopathologic study","volume":"87","author":"Hida","year":"2016","journal-title":"Neurology"},{"key":"R40-20230925","doi-asserted-by":"crossref","first-page":"e1768","DOI":"10.1212\/WNL.0000000000008443","article-title":"More prominent muscle involvement in patients with dermatomyositis with anti-Mi-2 autoantibodies","volume":"93","author":"Pinal-Fernandez","year":"2019","journal-title":"Neurology"},{"key":"R41-20230925","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2020.03.058","article-title":"Systematic retrospective study on 64 patients anti-Mi-2 dermatomyositis: a classic skin rash with a necrotizing myositis and high risk of malignancy","author":"Monseau","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"R42-20230925","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1093\/rheumatology\/kex516","article-title":"Muscle ischaemia associated with NXP2 autoantibodies: a severe subtype of juvenile dermatomyositis","volume":"57","author":"Aouizerate","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"R43-20230925","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1093\/rheumatology\/keu259","article-title":"Calcinosis in juvenile dermatomyositis is influenced by both anti-NXP2 autoantibody status and age at disease onset","volume":"53","author":"Tansley","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"R44-20230925","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.jaad.2017.12.010","article-title":"Antimelanoma differentiation-associated gene 5 (MDA5) dermatomyositis: A concise review with an emphasis on distinctive clinical features","volume":"78","author":"Kurtzman","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"R45-20230925","doi-asserted-by":"crossref","first-page":"e70","DOI":"10.1212\/WNL.0000000000009727","article-title":"Different phenotypes in dermatomyositis associated with anti-MDA5 antibody: Study of 121 cases","volume":"95","author":"Allenbach","year":"2020","journal-title":"Neurology"},{"key":"R46-20230925","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/jamaneurol.2020.0673","article-title":"Association of dermatomyositis sine dermatitis and with anti-nuclear matrix protein 2 autoantibodies","volume":"77","author":"Inoue","year":"2020","journal-title":"JAMA Neurol"},{"key":"R47-20230925","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1136\/annrheumdis-2019-215046","article-title":"Focused HLA analysis in Caucasians with myositis identifies significant associations with autoantibody subgroups","volume":"78","author":"Rothwell","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"R48-20230925","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1097\/BOR.0000000000000652","article-title":"Genetics of idiopathic inflammatory myopathies: insights into disease pathogenesis","volume":"31","author":"Rothwell","year":"2019","journal-title":"Curr Opin Rheumatol"},{"key":"R49-20230925","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.semarthrit.2019.03.005","article-title":"Novel susceptibility alleles in HLA region for myositis and myositis specific autoantibodies in Korean patients","volume":"49","author":"Kang","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"R50-20230925","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1093\/rheumatology\/kex021","article-title":"A longitudinal cohort study of the antisynthetase syndrome: increased severity of interstitial lung disease in black patients and patients with anti-PL7 and anti-PL12 autoantibodies","volume":"56","author":"Pinal-Fernandez","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"R51-20230925","doi-asserted-by":"crossref","DOI":"10.1007\/s12016-020-08786-6","article-title":"JAK inhibitors: prospects in connective tissue diseases","author":"You","year":"2020","journal-title":"Clin Rev Allergy Immunol"},{"key":"R52-20230925","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.3390\/jcm8112013","article-title":"Influence of antisynthetase antibodies specificities on antisynthetase syndrome clinical spectrum time course","volume":"8","author":"Cavagna","year":"2019","journal-title":"J Clin Med"},{"key":"R53-20230925","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.autrev.2019.05.002","article-title":"Anti-OJ autoantibodies: rare or underdetected?","volume":"18","author":"Vulsteke","year":"2019","journal-title":"Autoimmun Rev"},{"issue":"(Pt 9)","key":"R54-20230925","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1093\/brain\/awv192","article-title":"Anti-Jo-1 antibody-positive patients show a characteristic necrotizing perifascicular myositis","volume":"138","author":"Mescam-Mancini","year":"2015","journal-title":"Brain"},{"key":"R55-20230925","doi-asserted-by":"crossref","first-page":"e50","DOI":"10.1093\/brain\/aww125","article-title":"Perifascicular necrosis in antisynthetase syndrome beyond anti-Jo-1","volume":"139","author":"Uruha","year":"2016","journal-title":"Brain"},{"key":"R56-20230925","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1212\/WNL.0000000000001422","article-title":"Nuclear actin aggregation is a hallmark of antisynthetase syndrome-induced dysimmune myopathy","volume":"84","author":"Stenzel","year":"2015","journal-title":"Neurology"},{"key":"R57-20230925","doi-asserted-by":"crossref","first-page":"e513","DOI":"10.1212\/NXI.0000000000000513","article-title":"Seronegative patients form a distinctive subgroup of immune-mediated necrotizing myopathy","volume":"6","author":"Lim","year":"2019","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"R58-20230925","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1093\/rheumatology\/kew386","article-title":"Pediatric necrotizing myopathy associated with anti3-hydroxy-3-methylglutaryl-coenzyme A reductase antibodies","volume":"56","author":"Liang","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"R59-20230925","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13023-015-0277-y","article-title":"Inflammatory myopathy with antisignal recognition particle antibodies: case series of 100 patients","volume":"10","author":"Suzuki","year":"2015","journal-title":"Orphanet J Rare Dis"},{"key":"R60-20230925","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.pediatrneurol.2011.04.009","article-title":"Antisignal recognition particle myopathy in the first decade of life","volume":"45","author":"Suzuki","year":"2011","journal-title":"Pediatr Neurol"},{"key":"R61-20230925","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1136\/jnnp-2016-313166","article-title":"Clinical features and prognosis in anti-SRP and anti-HMGCR necrotising myopathy","volume":"87","author":"Watanabe","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R62-20230925","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.autrev.2018.09.008","article-title":"Myositis-specific autoantibodies, a cornerstone in immune-mediated necrotizing myopathy","volume":"18","author":"Anquetil","year":"2019","journal-title":"Autoimmun Rev"},{"key":"R63-20230925","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1212\/WNL.0000000000003160","article-title":"HLA-DRB1 alleles in immune-mediated necrotizing myopathy","volume":"87","author":"Ohnuki","year":"2016","journal-title":"Neurology"},{"key":"R64-20230925","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1002\/acr.23113","article-title":"Association of anti3-hydroxy-3-methylglutaryl-coenzyme A reductase autoantibodies with DRB1\u221707:01 and severe myositis in juvenile myositis patients","volume":"69","author":"Kishi","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R65-20230925","doi-asserted-by":"crossref","first-page":"e507","DOI":"10.1212\/WNL.0000000000004923","article-title":"Necrosis in anti-SRP+and anti-HMGCR+ myopathies: role of autoantibodies and complement","volume":"90","author":"Allenbach","year":"2018","journal-title":"Neurology"},{"key":"R66-20230925","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1136\/annrheumdis-2018-213518","article-title":"In vivo pathogenicity of IgG from patients with anti-SRP or anti-HMGCR autoantibodies in immune-mediated necrotising myopathy","volume":"78","author":"Bergua","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"R67-20230925","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/bpa.12772","article-title":"Sequestosome-1 (p62) expression reveals chaperone-assisted selective autophagy in immune-mediated necrotizing myopathies","volume":"30","author":"Fischer","year":"2020","journal-title":"Brain Pathol"},{"key":"R68-20230925","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/s41584-019-0186-x","article-title":"Inclusion body myositis: clinical features and pathogenesis","volume":"15","author":"Greenberg","year":"2019","journal-title":"Nat Rev Rheumatol"},{"key":"R69-20230925","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1097\/PAI.0b013e31827d7f16","article-title":"Major histocompatibility complex class I and II expression in idiopathic inflammatory myopathy","volume":"21","author":"Das","year":"2013","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"R70-20230925","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s40478-014-0154-2","article-title":"Myofiber HLA-DR expression is a distinctive biomarker for antisynthetase-associated myopathy","volume":"2","author":"Aouizerate","year":"2014","journal-title":"Acta Neuropathol Commun"},{"key":"R71-20230925","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.1093\/brain\/awz207","article-title":"Highly differentiated cytotoxic T cells in inclusion body myositis","volume":"142","author":"Greenberg","year":"2019","journal-title":"Brain"},{"key":"R72-20230925","doi-asserted-by":"crossref","first-page":"e558","DOI":"10.1212\/NXI.0000000000000558","article-title":"PD1 pathway in immune-mediated myopathies: pathogenesis of dysfunctional T cells revisited","volume":"6","author":"Knauss","year":"2019","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"R73-20230925","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1136\/annrheumdis-2017-212436","article-title":"Anti-NT5C1A autoantibodies are associated with more severe disease in patients with juvenile myositis","volume":"77","author":"Yeker","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"R74-20230925","doi-asserted-by":"crossref","first-page":"745","DOI":"10.3389\/fimmu.2019.00745","article-title":"Anti-NT5c1A autoantibodies as biomarkers in inclusion body myositis","volume":"10","author":"Amlani","year":"2019","journal-title":"Front Immunol"},{"key":"R75-20230925","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1136\/annrheumdis-2016-210282","article-title":"Cytosolic 5\u2019-nucleotidase 1A autoantibody profile and clinical characteristics in inclusion body myositis","volume":"76","author":"Lilleker","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"R76-20230925","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1136\/jnnp-2014-310008","article-title":"Seropositivity for NT5c1A antibody in sporadic inclusion body myositis predicts more severe motor, bulbar and respiratory involvement","volume":"87","author":"Goyal","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R77-20230925","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1097\/BOR.0000000000000536","article-title":"The clinico-serological spectrum of overlap myositis","volume":"30","author":"Fredi","year":"2018","journal-title":"Curr Opin Rheumatol"},{"key":"R78-20230925","doi-asserted-by":"crossref","first-page":"102465","DOI":"10.1016\/j.autrev.2020.102465","article-title":"Anti-RNP antibodies delineate a subgroup of myositis: a systematic retrospective study on 46 patients","volume":"19","author":"Wesner","year":"2020","journal-title":"Autoimmun Rev"},{"key":"R79-20230925","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1136\/annrheumdis-2018-214439","article-title":"Anti-Ku syndrome with elevated CK and anti-Ku syndrome with antidsDNA are two distinct entities with different outcomes","volume":"78","author":"Spielmann","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"R80-20230925","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/MD.0b013e31824d9cec","article-title":"Inflammatory myopathies with anti-Ku antibodies: a prognosis dependent on associated lung disease","volume":"91","author":"Rigolet","year":"2012","journal-title":"Medicine (Baltimore)"},{"key":"R81-20230925","doi-asserted-by":"crossref","first-page":"e2068","DOI":"10.1212\/WNL.0000000000005638","article-title":"Muscular and extramuscular clinical features of patients with anti-PM\/Scl autoantibodies","volume":"90","author":"De Lorenzo","year":"2018","journal-title":"Neurology"},{"key":"R82-20230925","doi-asserted-by":"crossref","first-page":"e1416","DOI":"10.1212\/WNL.0000000000007188","article-title":"Muscular and extramuscular features of myositis patients with anti-U1-RNP autoantibodies","volume":"92","author":"Casal-Dominguez","year":"2019","journal-title":"Neurology"},{"key":"R83-20230925","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1093\/brain\/aws106","article-title":"Inflammatory myopathies associated with antimitochondrial antibodies","volume":"135","author":"Maeda","year":"2012","journal-title":"Brain"},{"key":"R84-20230925","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.semarthrit.2017.06.004","article-title":"Inflammatory myopathy associated with antimitochondrial antibodies: a distinct phenotype with cardiac involvement","volume":"47","author":"Albayda","year":"2018","journal-title":"Semin Arthritis Rheum"},{"key":"R85-20230925","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/mus.26731","article-title":"Thigh muscle MRI findings in myopathy associated with antimitochondrial antibody","volume":"61","author":"Minamiyama","year":"2020","journal-title":"Muscle Nerve"},{"key":"R86-20230925","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"R87-20230925","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1161\/CIRCULATIONAHA.118.035898","article-title":"Immune checkpoint inhibitor-associated myositis: expanding the spectrum of cardiac complications of the immunotherapy revolution","volume":"138","author":"Anquetil","year":"2018","journal-title":"Circulation"},{"key":"R88-20230925","doi-asserted-by":"crossref","first-page":"e985","DOI":"10.1212\/WNL.0000000000006124","article-title":"Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer","volume":"91","author":"Touat","year":"2018","journal-title":"Neurology"},{"key":"R89-20230925","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jaut.2019.03.005","article-title":"Inflammatory myopathy associated with PD-1 inhibitors","volume":"100","author":"Seki","year":"2019","journal-title":"J Autoimmun"},{"key":"R90-20230925","doi-asserted-by":"crossref","first-page":"102455","DOI":"10.1016\/j.autrev.2019.102455","article-title":"Emerging PD-1 and PD-1L inhibitors-associated myopathy with a characteristic histopathological pattern","volume":"19","author":"Matas-Garc\u00eda","year":"2020","journal-title":"Autoimmun Rev"}],"container-title":["Current Opinion in Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/WCO.0000000000000855","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T08:17:53Z","timestamp":1695629873000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/WCO.0000000000000855"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,25]]},"references-count":90,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/wco.0000000000000855","relation":{},"ISSN":["1350-7540","1473-6551"],"issn-type":[{"value":"1350-7540","type":"print"},{"value":"1473-6551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,25]]}}}